Copyright © 2002 American Medical Association. All rights reserved. From: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med. 2002;162(14):1568-1576. doi:10.1001/archinte.162.14.1568 Figure Legend: Effect of extended-release (ER) niacin, 1000 and 1500 mg/d, on the primary end point, high-density lipoprotein cholesterol (HDL-C) level, in patients with type 2 diabetes. Dose-related increases in HDL-C levels were evident in patients receiving ER niacin compared with placebo (P<.05 [asterisk]). Date of download: 11/4/2017 Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2002 American Medical Association. All rights reserved. From: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med. 2002;162(14):1568-1576. doi:10.1001/archinte.162.14.1568 Figure Legend: Effect of extended-release (ER) niacin, 1000 and 1500 mg/d, on the primary end point, triglyceride (TG) level, in patients with type 2 diabetes. Dose-related reductions in TG levels were evident in patients receiving ER niacin compared with placebo (P<.05 [asterisk]) and with patients receiving 1000 compared with 1500 mg/d of ER niacin (P<.05 [dagger]). Date of download: 11/4/2017 Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2002 American Medical Association. All rights reserved. From: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med. 2002;162(14):1568-1576. doi:10.1001/archinte.162.14.1568 Figure Legend: Effect of extended-release (ER) niacin, 1000 and 1500 mg/d, on the secondary end point, low-density lipoprotein cholesterol (LDL-C) level, in patients with type 2 diabetes. A reduction in LDL-C levels was observed only in patients receiving the 1500-mg/d dosage of ER niacin in this population with low LDL-C levels at baseline (P<.05 compared with patients receiving placebo [asterisk] and those receiving 1000-mg/d ER niacin [dagger]). Date of download: 11/4/2017 Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2002 American Medical Association. All rights reserved. From: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med. 2002;162(14):1568-1576. doi:10.1001/archinte.162.14.1568 Figure Legend: The effect of extended-release (ER) niacin, 1000 and 1500 mg/d, on the primary safety variable, hemoglobin (HbA1c) level (as a measure of glycemic control), in patients with type 2 diabetes. Minimal changes are observed among patients treated with ER niacin (P= .048 [asterisk] compared with placebo). Date of download: 11/4/2017 Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2002 American Medical Association. All rights reserved. From: Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial Arch Intern Med. 2002;162(14):1568-1576. doi:10.1001/archinte.162.14.1568 Figure Legend: Effect of extended-release (ER) niacin, 1000 and 1500 mg/d, on median fasting blood glucose (FBG) levels in patients with type 2 diabetes. Initial small increases in FBG levels in both ER niacin groups returned to baseline levels by week 16. To convert FBG levels to millimoles per liter, multiply by 0.0555. Asterisk indicates P<.05 compared with baseline. Date of download: 11/4/2017 Copyright © 2002 American Medical Association. All rights reserved.